Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.

Anaplastic large cell lymphomas (ALCLs) represent a subset of lymphomas in which the anaplastic lymphoma kinase (ALK) gene is frequently fused to the nucleophosmin (NPM) gene. We previously demonstrated that the constitutive phosphorylation of ALK chimeric proteins is sufficient to induce cellular transformation in vitro and in vivo and that ALK activity is strictly required for the survival of ALK-positive ALCL cells. To elucidate the signaling pathways required for ALK-mediated transformation and tumor maintenance, we analyzed the transcriptomes of multiple ALK-positive ALCL cell lines, abrogating their ALK-mediated signaling by inducible ALK RNA interference (RNAi) or with potent and cell-permeable ALK inhibitors. Transcripts derived from the gene expression profiling (GEP) analysis uncovered a reproducible signature, which included a novel group of ALK-regulated genes. Functional RNAi screening on a set of these ALK transcriptional targets revealed that the transcription factor C/EBPbeta and the antiapoptotic protein BCL2A1 are absolutely necessary to induce cell transformation and/or to sustain the growth and survival of ALK-positive ALCL cells. Thus, we proved that an experimentally controlled and functionally validated GEP analysis represents a powerful tool to identify novel pathogenetic networks and validate biologically suitable target genes for therapeutic interventions.

[1]  Anne E Carpenter,et al.  A Lentiviral RNAi Library for Human and Mouse Genes Applied to an Arrayed Viral High-Content Screen , 2006, Cell.

[2]  S. Mohammed,et al.  p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. , 2005, Blood.

[3]  J. Kutok,et al.  Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Wasik,et al.  Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. , 2001, Cancer research.

[5]  T. Arakawa,et al.  Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system , 1997, Oncogene.

[6]  S. Bicciato,et al.  Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma , 2005, Oncogene.

[7]  D. Ramji,et al.  CCAAT/enhancer-binding proteins: structure, function and regulation. , 2002, The Biochemical journal.

[8]  Arjan,et al.  High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma , 2005, Journal of Clinical Pathology.

[9]  T. Golub,et al.  Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. , 2006, Cancer cell.

[10]  Wei Li,et al.  CCAAT enhancer- binding protein beta is required for normal hepatocyte proliferation in mice after partial hepatectomy. , 1998, The Journal of clinical investigation.

[11]  S. Morris,et al.  Nucleophosmin-Anaplastic Lymphoma Kinase of Large-Cell Anaplastic Lymphoma Is a Constitutively Active Tyrosine Kinase That Utilizes Phospholipase C-γ To Mediate Its Mitogenicity , 1998, Molecular and Cellular Biology.

[12]  E. Lander,et al.  Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. , 2002, Cancer cell.

[13]  T. Golub,et al.  A Mechanism of Cyclin D1 Action Encoded in the Patterns of Gene Expression in Human Cancer , 2003, Cell.

[14]  R. Taulli,et al.  15-Deoxy-delta 12,14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-kappa B activity and down-regulation of antiapoptotic proteins. , 2005, Blood.

[15]  A. Morales,et al.  High expression of Bfl‐1 contributes to the apoptosis resistant phenotype in B‐cell chronic lymphocytic leukemia , 2005, International journal of cancer.

[16]  M. Wiznerowicz,et al.  Conditional Suppression of Cellular Genes: Lentivirus Vector-Mediated Drug-Inducible RNA Interference , 2003, Journal of Virology.

[17]  Y. Shyr,et al.  Histology Impacts the Outcome of Peripheral T-Cell Lymphomas after High Dose Chemotherapy and Stem Cell Transplant , 2004, Leukemia & lymphoma.

[18]  C. Zahnow.  CCAAT/enhancer binding proteins in normal mammary development and breast cancer , 2002, Breast Cancer Research.

[19]  D. Levy,et al.  Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target , 2005, Nature Medicine.

[20]  B. Li,et al.  Expression profiling reveals off-target gene regulation by RNAi , 2003, Nature Biotechnology.

[21]  S. Levy,et al.  Expression of the Bcl-2 family member A1 is developmentally regulated in T cells. , 1999, International immunology.

[22]  T. Grogan,et al.  Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures , 2005, Molecular Cancer Therapeutics.

[23]  T. Hunter,et al.  C/EBPbeta phosphorylation by RSK creates a functional XEXD caspase inhibitory box critical for cell survival. , 2001, Molecular cell.

[24]  J. Rothman,et al.  Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway , 2006, The Journal of cell biology.

[25]  S. Morris,et al.  Translocations involving anaplastic lymphoma kinase (ALK) , 2001, Oncogene.

[26]  R. Taulli,et al.  Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. , 2006, Blood.

[27]  Malay Mandal,et al.  The BCL2A1 gene as a pre–T cell receptor–induced regulator of thymocyte survival , 2005, The Journal of experimental medicine.

[28]  Liming Yang,et al.  A loss-of-function RNA interference screen for molecular targets in cancer , 2006, Nature.

[29]  K. Pulford,et al.  Expression of the ALK tyrosine kinase gene in neuroblastoma. , 2000, The American journal of pathology.

[30]  R. Bernards,et al.  A Genetic Screen Identifies PITX1 as a Suppressor of RAS Activity and Tumorigenicity , 2005, Cell.

[31]  G. Inghirami,et al.  NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. , 2003, Blood.

[32]  K. Umezawa,et al.  JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma. , 2005, Cancer research.

[33]  S. Nelson,et al.  Differential Induction of Glioblastoma Migration and Growth by Two Forms of Pleiotrophin* , 2005, Journal of Biological Chemistry.

[34]  D. Levy,et al.  Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death , 2002, Oncogene.

[35]  M. Raffeld,et al.  The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene up‐regulation in rat la fibroblasts , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  L. Chin,et al.  A Genetic Screen for Candidate Tumor Suppressors Identifies REST , 2005, Cell.

[37]  Antonio Martínez,et al.  NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein beta in ALK-positive anaplastic large cell lymphoma. , 2006, Blood.

[38]  P. Trempat,et al.  Isolation of differentially expressed genes in NPM‐ALK‐positive anaplastic large cell lymphoma , 2002, British journal of haematology.

[39]  B. Ruggeri,et al.  Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. , 2006, Blood.

[40]  E. Jaffe,et al.  Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. , 2000, Blood.

[41]  C. Naeve,et al.  ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK) , 1997, Oncogene.

[42]  R. Küppers,et al.  Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma. , 2006, Haematologica.

[43]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.

[44]  B. Dörken,et al.  A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. , 2005, Blood.

[45]  G. Rassidakis,et al.  Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. , 2005, Blood.

[46]  W. Sanger,et al.  Expression of ALK1 and p80 in Inflammatory Myofibroblastic Tumor and Its Mesenchymal Mimics: A Study of 135 Cases , 2002, Modern Pathology.

[47]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[48]  R. Smart,et al.  CCAAT/enhancer binding protein-β is a mediator of keratinocyte survival and skin tumorigenesis involving oncogenic Ras signaling , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[49]  K. Pulford,et al.  Anaplastic lymphoma kinase proteins in growth control and cancer , 2004, Journal of cellular physiology.

[50]  G. Delsol,et al.  Oncogenic protein tyrosine kinases , 2004, Cellular and Molecular Life Sciences CMLS.